HomeCompareOPHLF vs MO

OPHLF vs MO: Dividend Comparison 2026

OPHLF yields 3.22% · MO yields 9.11%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 OPHLF wins by $9.77M in total portfolio value
10 years
OPHLF
OPHLF
● Live price
3.22%
Share price
$14.55
Annual div
$0.47
5Y div CAGR
76.7%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$9.80M
Annual income
$8,123,319.23
Full OPHLF calculator →
MO
Altria Group Inc.
● Live price
9.11%
Share price
$44.80
Annual div
$4.08
5Y div CAGR
4.3%
Payout ratio
78%
After 10 yrs · $10,000 · DRIP
Portfolio value
$27.7K
Annual income
$4,052.72
Full MO calculator →

Portfolio growth — OPHLF vs MO

📍 OPHLF pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodOPHLFMO
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, OPHLF + MO cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
OPHLF pays
MO pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

OPHLF
Annual income on $10K today (after 15% tax)
$273.36/yr
After 10yr DRIP, annual income (after tax)
$6,904,821.35/yr
MO
Annual income on $10K today (after 15% tax)
$774.11/yr
After 10yr DRIP, annual income (after tax)
$3,444.81/yr
At 15% tax rate, OPHLF beats the other by $6,901,376.53/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of OPHLF + MO for your $10,000?

OPHLF: 50%MO: 50%
100% MO50/50100% OPHLF
Portfolio after 10yr
$4.91M
Annual income
$4,063,685.97/yr
Blended yield
82.72%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on MO right now

OPHLF
No analyst data
Altman Z
4.8
Piotroski
8/9
MO
Analyst Ratings
16
Buy
9
Hold
1
Sell
Consensus: Buy
Price Target
$61.25
+36.7% upside vs current
Range: $47.00 — $68.00
Altman Z
3.2
Piotroski
7/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

OPHLF buys
0
MO buys
0
No recent congressional trades found for OPHLF or MO in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricOPHLFMO
Forward yield3.22%9.11%
Annual dividend / share$0.47$4.08
Payout ratio50%78%
1-year div growth0%4.1%
5-year div CAGR76.7%4.3%
Portfolio after 10y$9.80M$27.7K
Annual income after 10y$8,123,319.23$4,052.72
Total dividends collected$9.63M$20.9K
Payment frequencyquarterlyquarterly
SectorStockConsumer Staples

Year-by-year: OPHLF vs MO ($10,000, DRIP)

YearOPHLF PortfolioOPHLF Income/yrMO PortfolioMO Income/yrGap
1← crossover$11,268$568.26$10,740$949.88+$528.00OPHLF
2$13,114$1,057.44$11,601$1,086.84+$1.5KOPHLF
3$16,065$2,032.36$12,608$1,250.75+$3.5KOPHLF
4$21,301$4,111.31$13,792$1,448.20+$7.5KOPHLF
5$31,794$9,002.23$15,190$1,687.69+$16.6KOPHLF
6$56,209$22,189.83$16,851$1,980.28+$39.4KOPHLF
7$124,928$64,784.43$18,838$2,340.48+$106.1KOPHLF
8$371,454$237,780.36$21,230$2,787.44+$350.2KOPHLF
9$1,564,997$1,167,541.06$24,130$3,346.72+$1.54MOPHLF
10$9,797,866$8,123,319.23$27,676$4,052.72+$9.77MOPHLF

OPHLF vs MO: Complete Analysis 2026

OPHLFStock

Ono Pharmaceutical Co., Ltd., together with its subsidiaries, produces, purchases, and sells pharmaceuticals and diagnostic reagents worldwide. It offers OPDIVO intravenous infusions for the treatment of malignant tumors; KYPROLIS for intravenous injection; EMEND capsules/PROEMEND intravenous injections for chemotherapy-induced nausea and vomiting; DEMSER capsules for improvement of the symptoms in patients with pheochromocytoma; and MEKTOVI, VELEXBRU, and ADLUMIZ tablets, as well as BRAFTOVI capsules for malignant tumors. The company also provides GLACTIV and FORXIGA tablets for type 2 diabetes; FORXIGA tablets for the treatment of diabetes; ONOACT injections for tachyarrhythmia; OPALMON tablets to treat peripheral circulatory disorder; CORALAN for treatment of chronic heart failure; ORENCIA injections for rheumatoid arthritis; RIVASTACH patches for Alzheimer's disease; ONGENTYS tablets for the treatment of Parkinson's disease; PARSABIV, an intravenous injection for dialysis patients; STAYBLA tablets for overactive bladder; ONON capsules and dry syrups for bronchial asthma and allergic rhinitis; and JOYCLU intra-articular injection for the improvement of joint function, as well as RECALBON tablets for osteoporosis. In addition, it is developing products for esophageal, urothelial carcinoma, Hodgkin's lymphoma, ovarian, bladder, prostate, hepatocellular carcinoma, pancreatic, biliary tract, virus positive/negative solid carcinoma, gastric, esophageal, urothelial, hepatocellular, thyroid, colorectal, melanoma, acute myeloid leukemia, non-small cell lung cancer, primary central nervous system lymphoma, myelodysplastic syndrome, polymyositis/dermatomyositis, tachyarrhythmia, pemphigus, generalized scleroderma, enthesopathy, diabetic polyneuropathy, neurodegenerative, autoimmune, narcolepsy, and thrombosis. The company was founded in 1717 and is headquartered in Osaka, Japan.

Full OPHLF Calculator →

MOConsumer Staples

Altria is a Dividend King with 54+ consecutive years of dividend increases — one of the longest streaks in American corporate history. While cigarette volumes decline, pricing power and new product categories (oral nicotine pouches via NJOY) support cash flows. The near-9% yield is among the highest in the S&P 500.

Full MO Calculator →
📬

Get this OPHLF vs MO comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

OPHLF vs SCHDOPHLF vs JEPIOPHLF vs OOPHLF vs KOOPHLF vs MAINOPHLF vs PMOPHLF vs BTIOPHLF vs PG

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.